Last reviewed · How we verify
NCT07466251: PISTIAS-3
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
Phase 4 trial testing Rucacuzumab plus standard therapy in Acute Ischemic Stroke AIS in 1,212 participants. Not yet recruiting.
31 December 2028
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 1,212 |
| Start date | 1 September 2026 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2029 |
| Sites | 19 locations across China |
Drugs / interventions tested
- Rucacuzumab plus standard therapy — full drug profile →
- Recaticimab plus placebo in combination with standard therapy — full drug profile →
Conditions studied
- Acute Ischemic Stroke AIS — all drugs for Acute Ischemic Stroke AIS →
- Intracranial Atherosclerosis ICAS — all drugs for Intracranial Atherosclerosis ICAS →
- Atherosclerotic Plaque — all drugs for Atherosclerotic Plaque →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 30 to 80, any sex, with Acute Ischemic Stroke AIS or Intracranial Atherosclerosis ICAS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective, multicenter, double-blind, randomized, placebo-controlled clinical trial designed to evaluate whether early administration of PCSK9 inhibitors can effectively improve functional outcomes at 90 days in patients with ischemic stroke (AIS) associated with intracranial atherosclerotic stenosis (ICAS), primarily assessed using the modified Rankin Scale at 90 days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07466251
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Ischemic Stroke AIS
Currently open trials in the same condition.
- NCT07052045 — One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy · NA · recruiting
- NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
- NCT07084012 — A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS · Phase 2 · recruiting
- NCT06320431 — ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 · Phase 3 · recruiting
- NCT06052969 — Pulse Endovascular ReperFUSION for Acute Ischemic Stroke · NA · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
- NCT07406308 — A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07466251 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07466251.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing